Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Wayne State Univ

Neither a doctor nor a teaching hospital

Research payments

$954,270

187 payments

Through program year 2025, Wayne State Univ is reported as receiving $954,270 in research payments, across 187 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $24,342 9
2024 Research $21,453 4
2023 Research $24,831 7
2022 Research $114,169 17
2021 Research $63,469 24
2020 Research $255,260 60
2019 Research $450,745 66

Breakdown

Who paid Research payments · program years 2019–2025
  1. Siemens Medical Solutions USA, Inc. $355,547 23 payments
  2. Novo Nordisk AS $145,982 51 payments
  3. Janssen Research & Development, LLC $129,322 70 payments
  4. Amgen Inc. $93,265 2 payments
  5. AstraZeneca Pharmaceuticals LP $85,249 9 payments
  6. Alexion Pharmaceuticals, Inc. $46,912 2 payments
  7. Boehringer Ingelheim Pharmaceuticals, Inc. $37,208 5 payments
  8. AbbVie, Inc. $24,431 6 payments
  9. Janssen Pharmaceuticals, Inc $17,000 1 payment
  10. AstraZeneca UK Limited $10,173 4 payments
Studies the money was for Research payments · program years 2019–2025
  1. PBNP ED sample collection $307,156 13 payments
  2. A Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy of Ivabradine Initiated at the Time of Discharge from the Observation Unit (OBSERVE-IVA) $93,265 2 payments
  3. Haem-4436 $92,885 16 payments
  4. 52 wks Eff. & Saf. Ph III in Paediatrics $44,903 11 payments
  5. A Double masked Placebo controlled Study with Open label Period to Evaluate the Efficacy and Safety of MEDI551 in Adult Subjects with Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders $43,125 2 payments
  6. A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension PAH $30,878 19 payments
  7. A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE (LIBREXIA-STROK) $24,342 9 payments
  8. A Phase 3, Open Label, Multicenter Study of ALXN1210 in Children and Adolescents with Atypical Hemolytic Uremic Syndrome aHUS $23,992 1 payment
  9. A Phase 4 Randomized Clinical Trial of Andexanet Alfa, Andexanet Alfa for Injection, in Acute Intracranial Hemorrhage in Patients Receiving An Oral Factor Xa Inhibitor $22,920 1 payment
  10. A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH) $20,858 18 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record